Androgens and breast cancer risk

Gynecol Endocrinol. 2012 Mar:28 Suppl 1:46-9. doi: 10.3109/09513590.2012.651925.

Abstract

Transdermal testosterone supplementation is a treatment option for postmenopausal women with distressful decreased libido. Side effects are minor, but there is a long-term safety concern with respect to breast cancer, as women with high testosterone serum levels appear to be at a significantly increased risk to have or to develop breast cancer within a few years. Epidemiological studies of sufficient duration to study long-term effects of testosterone supplementation are limited, both in number and in methodological quality and are, therefore, inconclusive. Preclinical studies do not provide evidence for an androgen receptor-mediated stimulating effect of androgens on breast epithelium. However, one biologically plausible possibility, which cannot be ruled out, is that exogenous androgens become mitogenic after aromatization into bioactive oestradiol, either in peripheral fat or within the breast or even within small occult tumours. The evidence available so far makes counselling women interested in testosterone supplementation for distressful low sexual desire, more of an art than science.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Androgens / adverse effects*
  • Androgens / therapeutic use
  • Animals
  • Breast Neoplasms / chemically induced
  • Breast Neoplasms / etiology*
  • Carcinoma / chemically induced
  • Carcinoma / etiology*
  • Counseling / methods
  • Estrogen Replacement Therapy / adverse effects
  • Female
  • Humans
  • Postmenopause / drug effects
  • Postmenopause / psychology
  • Risk Factors
  • Sexual Dysfunctions, Psychological / drug therapy

Substances

  • Androgens